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A B S T R A C T
The beneficial or detrimental effects of androgens on the cardiovascular system are debated.
Endothelial progenitor cells are bone-marrow-derived cells involved in endothelial healing
and angiogenesis, which promote cardiovascular health. Oestrogens are potent stimulators of
endothelial progenitor cells, and previous findings have indicated that androgens may improve
the biology of these cells as well. In the present study, we show that testosterone and its
active metabolite dihydrotestosterone exert no effects on the expansion and function of late
endothelial progenitors isolated from the peripheral blood of healthy human adult males, whereas
they positively modulate early ‘monocytic’ endothelial progenitor cells. In parallel, we show that
castration in rats is followed by a decrease in circulating endothelial progenitor cells, but that
testosterone and dihydrotestosterone replacement fails to restore endothelial progenitor cells
towards normal levels. This is associated with persistently low oestrogen levels after androgen
replacement in castrated rats. In a sample of 62 healthy middle-aged men, we show that circulating
endothelial progenitor cell levels are more directly associated with oestradiol, rather than with
testosterone, concentrations. In conclusion, our results collectively demonstrate that androgens
exert no direct effects on endothelial progenitor cell biology in vitro and in vivo.
INTRODUCTION
In the last decade, our knowledge on vascular homoeo-
stasis has significantly changed thanks to the discovery
of EPCs (endothelial progenitor cells) in adult human
blood [1]. EPCs originally reside in the bone marrow
and other putative niches [2], they can be mobilized in
the peripheral circulation in response to many stimuli
and, once in the bloodstream, actively take part in
endothelial repair and formation of new blood vessels [3].
Many experimental studies have substantiated thismodel,
suggesting that vascular homoeostasis depends not only
on resident cells, but also on the relevant contribu-
tion of circulating EPCs [4]. Reconstitution and main-
tenance of an intact endothelial layer is a crucial homo-
eostatic function of the cardiovascular system because
endothelial damage is the earliest step in the atherogenetic
process [5]. Angiogenesis is another fundamental event in
health and disease, as it is involved in physiological condi-
tions, such as body growth and themenstrual cycle, and in
the setting of pathological conditions, such as ischaemic
syndromes and wound healing. Being closely linked to
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endothelial repair and angiogenesis, EPCs represent an
integrated component of the cardiovascular system [6].
Consistent with this view, it has been shown that subjects
with risk factors for or established CVD (cardiovascular
disease) have a depletion in circulating EPCs [7].
Interestingly, patients with lower levels of EPCs in the
bloodstream have a higher risk of cardiovascular events
[8–10]. These findings have suggested that a depletion in
EPCs is a pathogenic event that, through the inability
to maintain an intact endothelium and to promote
angiogenesis, translates risk factors into the develop-
ment and progression of CVD [5]. Moreover, the
comprehensive role of EPCs in CVD has suggested that
EPC levels may be used as a surrogate marker of vascular
damage and overall cardiovascular risk [11].
Cardiovascular risk gradients are primarily driven by
gender: women of a reproductive age have a much lower
incidence of cardiovascular events than age-matched
men [12]. This is generally attributed to the vasculopro-
tective actions of female oestrogens, which are mediated
by favourable effects on lipid profile, and inflammatory
and haemostatic parameters [13]. Interestingly, experi-
mental studies show that E2 (17β-oestradiol) mobilizes
EPCs from the bonemarrow and enhances EPC function
[14,15]. We have demonstrated that women have higher
levels and better functions of EPCs than age-matched
men thanks to the cyclic EPC stimulation for endometrial
regeneration [16]. Therefore sex-hormone-driven gen-
der-specific modulation of EPCs may be one mechanism
that accounts for the gender gradient in cardiovascular
risk. There are some results suggesting that EPCs may be
also regulated by androgens. In one study, hypogonadal
men had a depletion in ex-vivo-determined circulating
EPCs,whichwere restoredbypharmacological treatment
with testosterone [17]. In another study, potential favour-
able effects of androgens on EPCs were shown in vitro
[18]; however, these findingswere probably influenced by
the methods used to enumerate and isolate EPCs [19,20],
which have profound effects on study results [20,21]. In
the present study, we have explored the role of androgens
in EPC biology by showing: (i) the relationships among
EPC levels, and testosterone and E2 concentrations in
healthy men; (ii) the effects of testosterone and its active
metabolite DHT (dihydrotestosterone) on early EPCs
and late EPCs isolated in vitro using a standardized and
extensively characterized protocol; and (iii) the effects of
testosterone deficiency on circulatingEPCs in a ratmodel
of primary hypogonadism in vivo.
MATERIALS AND METHODS
Patients
Healthy men were recruited from a local community
of middle-aged individuals who responded to an
advertisement for health screening. Exclusion criteria
were any recent (within 3 months) acute or chronic
disease or infection, known CVD (ruled out by minimal
criteria, including history and physical examination) and
immunological disease. On the basis of these criteria, 62
healthy men were included. Age, smoking habit (of one
or more cigarettes), BMI (body mass index; calculated
from height and weight), waist circumference, and
systolic and diastolic BP (blood pressure) were recorded.
Blood samples were drawn for the determination of
plasma fasting glucose, lipid profile [total cholesterol,
HDL (high-density lipoprotein)-cholesterol and triacyl-
glycerol (triglyceride) concentrations], sex hormones (E2
and total testosterone) and progenitor cells.
Informed consent was obtained from all subjects. The
study protocol was in accordance with the Declaration
of Helsinki (2000) of the World Medical Association,
and has been approved by the local Ethics Committee.
Cell culture
For the isolation of late EPCs, buffy coats of young
(40 year old) male healthy blood donors were used, and
culture was performed as described previously [11,16].
Briefly, PBMCs (peripheral blood mononuclear cells)
were separated using a Ficoll density gradient (Sigma).
Cells were plated on to six-well fibronectin-coated plates
(Becton Dickinson) at a density of 6× 106 cells/well,
and were grown in supplemented endothelial cell growth
medium (Clonetics) for 15 days. Culture medium was
changed first on day 4 and then every 2 days. Phenotyp-
ical characterization was performed at day 15. To study
the effects of androgens on cultured EPCs, starting from
day 1, growth medium was supplemented with 1, 10 or
100 nmol/l testosterone orDHT.As a positive control, E2
at 1, 10 or 100 nmol/l was used. With this culture system,
attaching cells rapidly assume an endothelial-like shape
and, starting from days 3–6 of culture, cells proliferate
in clusters or small colonies made up of a central core
of rounded cells surrounded by radiating spindle-shaped
cells. Starting from days 10–12, cells also organize into
large colonies of cobblestone confluent cells, which are
considered endothelial colonies. Clusters were quantified
every 3 days starting from day 6 until day 15 in ten
randomly selected microscopic fields. It is currently
agreed that cultures prolonged for 2 weeks allow positive
selection of true EPCs that should represent the only
surviving cell type [19,20]. The AUC (area under the
curve) of the number of EPC clusters over days 6–15 was
taken to represent the clonogenic expansion capacity.
Early EPCs were cultured from PBMCs of young
male healthy blood donors, as described previously
[22]. Briefly, cells were plated on to six-well fibronectin-
coated plates at a density of 6× 106 cells/well, and
were grown in supplemented endothelial cell growth
medium (Clonetics) without a medium change. After
4 days, cells were washed and stained with DiI (1,1′-
dioctadecyl-3,3,3′,3′-tetramethylindocarbocyanime
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perchlorate)–AcLDL (acetylated low-density lipopro-
tein) and Ulex lectin (see below). Cells double-positive
for DiI–AcLDL and lectin were considered as early
EPCs and were counted in ten randomly selected high-
power fields.
Characterization of cultured EPCs
After 15 days, late EPCs were characterized to confirm
the endothelial phenotype. After washing with PBS,
cells were incubated at 37 ◦C with 1 μg/ml DiI–AcLDL
(Molecular Probes) for 1 h, followed by incubation in
the dark with 15 mg/ml FITC-conjugated Ulex lectin
(Sigma) for 2 h. Nuclei were stained in blue withHoechst
33258 (Sigma).Dual-positivity for thesemarkers has been
suggested previously as a necessary, but not sufficient,
criterion to identify EPCs [19]. For further characteriz-
ation, we stained putative EPCs with other endothelial
markers. Cells were fixed and incubated with anti-vWf
(von Willebrand factor) (Dako Cytomation), anti-KDR
(kinase insert domain-containing receptor) (Santa Cruz
Biotechnology) and anti-CD31 (Chemicon Interna-
tional) antibodies and secondary Cy2-conjugated anti-
(rabbit Ig) and anti-(mouse Ig) antibodies (Chemicon
International). Positive cells were then visualized under
a fluorescent microscope. For a further methodological
confirmation of endothelial phenotype, cultured EPCs
were detached using EDTA and analysed by flow cyto-
metry for the expression of CD34 (a stem cell marker),
KDR (R&D Systems) and CD31 (Becton Dickinson).
As an in vivo functional assay, we injected isolated
EPCs into male Sprague–Dawley rat (Charles River)
muscles subjected to 2 h of ischaemia/reperfusion
injury, as described previously [16,23] The protocol was
approved by the local ethics committee at the Institutions.
Meanwhile, cultured EPCs were detatched with EDTA,
washed with PBS and stained with 0.5 μg/ml of the
orange dye CMTMR [5-(and-6)-(4-chloromethyl-benz-
oyl-amino)-tetramethylrhodamine] (Molecular Probes).
Immediately after reperfusion, the TA (tibialis anterior)
muscle was exposed and 2× 106 of labelled EPCs/kg of
bodyweightwere injected intramuscularly.Animalswere
killed 2 weeks afterEPC implantation and theTAmuscles
were harvested. Muscle capillaries were stained using an
anti-(rat CD31) antibody (Chemicon International) on
5 μm muscle cryosections and were observed under a
fluorescent microscope. Nuclei were counter-stained in
blue with Hoescht 33358. Elongated cellular structures
containing both rat CD31- and CMTMR-positive cells
were considered chimaeric vessels bearing human EPCs.
Adhesion assay
The functional property of late EPCs to adhere to
mature endothelium was evaluated in vitro, as described
previously [11,16]. For this purpose, a monolayer of
HUVECs (human umbilical vein endothelial cells;
Clonetics) was prepared 48 h before the assay by plating
2× 105 cells/cm2 at early passages. EPCs were labelled
with DiI–AcLDL as described above, and 1× 105 cells
were added to each well and incubated for 2 h at 37 ◦C.
Non-attached cells were gently removed with PBS, and
adherent EPCs were fixed with 4% paraformaldehyde
in PBS and were counted in ten random fields.
Expression of the AR (androgen receptor)
Late EPCs were assayed for the expression of the
AR using IF (immunofluorescence) and WB (Western
blot) analysis. IF was performed with cells stained
with the mouse monoclonal anti-(human AR) antibody
F39.4.1, which is directed against the N-terminal part
of the AR protein (amino acids 301–320; Santa Cruz
Biotechnology), and a secondary FITC-conjugated anti-
(rabbit IgG) antibody. Nuclei were stained in blue with
Hoechst 33358 (Sigma). For WB analysis, EPCs were
detached with EDTA, and total protein extracts were ob-
tained by cell lysis with a ice-cold buffer [20 mmol/l
Tris/HCl (pH 7.4), 150 mmol/l NaCl, 5 mmol/l EDTA,
1.5% Niaproof, 1.0 mmol/l Na3PO4, 0.1% SDS and
0.5 mmol/l PMSF] with proteases inhibitors added. Pro-
tein concentrationswere determined using theBCAassay
(Pierce). Proteins were then separated by SDS/PAGE,
transferred on to nitrocellulose membranes (Hybond
ECL; Amersham Biosciences) and blocked overnight
with 5% (w/v) non-fat milk in PBS/0.05% Tween
20. Membranes were probed with a primary anti-AR
antibody (Santa Cruz Biotechnology). After incubation
with the appropriate HRP (horseradish peroxidase)-
conjugated secondary antibodies (Amersham Bio-
sciences), immunoreactive proteins were visualized
by chemiluminescence using the SuperSignal WestPico
chemiluminescent substrate (Pierce). A positive control
was provided by a prostate protein extract. Proteins were
also extracted forWBanalysis fromHUVECs (Clonetics)
at passage 4–5 and PBMCs immediately after isolation.
Aromatase activity
As an indirect assay of aromatase activity, confluent
late EPCs were incubated with 0, 1, 10 or 100 nmol/l
testosterone for 24 h and E2 concentrations were then
measured (RIA oestradiol assay; Immunotech) in the
culture medium supernatant. As a negative control, a
cell-free system was prepared, consisting of plates filled
with culture medium without cells, and incubated for
24 h with identical concentrations of testosterone.
Rat castration
To study in vivo the effects of androgen deprivation and
restoration, we used a rat model of castration followed
by androgen replacement. The protocol was approved
by the local ethics committee of the Institutions. Briefly,
adult male Sprague–Dawley rats underwent bilateral
castration under ketamine/xylazine anaesthesia (50 and
20 mg/kg of body weight intraperitoneally respectively).
A sham operation consisted of opening the scrotum,
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Figure 1 Progenitor cell count in healthy men
Left-hand panels, the gating strategy used to enumerate CD34+KDR+ cells in
healthy men. First, CD34+ cells were identified in the ungated white blood
cell population. Then the expression of KDR was assayed in the CD34+ cell
gate in order to identify and quantify CD34+KDR+ cells (indicated by the oval).
Right-hand panel, CD34+KDR+ cells were lower in men with high testosterone and
low E2 compared with subjects with low testosterone and high E2. *P  0.05.
Where not specified, the x- and y-axis represent arbitrary fluorescence units. T,
testosterone.
manipulating the gonads and suturing the overlying
skin. After a 4-week period of recovery, blood samples
were drawn for determination of sex hormones (RIA
oestradiol and total testosterone assays; Immunotech)
and rat progenitor cell count. Then castrated rats were
implanted subcutaneously with a silicone tube (internal
diameter, 1.7 mm; external diameter, 3.4 mm; length,
10 mm; Dow-Corning) containing crystals of either
testosterone (n= 3) or DHT (n= 3). At 2 weeks after the
beginning of androgen treatment, blood was taken by
heart puncture under deep urethane anaesthesia.
Progenitor cell counts
Circulating progenitor cells were analysed by flow
cytometry on peripheral blood samples as described
previously in detail [7,20]. Briefly, after red cell lysis, 10 μl
of whole blood was incubated with FITC-conjugated
anti-CD34 and PE (phycoerythrin)-conjugated anti-
KDR. CD34+ cells were gated and then this population
was assessed for KDR expression in the mononuclear cell
fraction (Figure 1). A total of 1× 105 cells were always ac-
quired, and human EPCs were defined as CD34+KDR+.
Rat progenitor cells were defined as Sca-1+c-kit+ and
Sca-1+CD31+ cells using PE-conjugated anti-(mouse
Sca-1), FITC-conjugated anti-c-kit or FITC-conjugated
anti-(rat CD31) monoclonal antibodies, and the same
gating strategy used for human cells (see Figure 5). We
have shown previously [23] that the rat Sca-1+/c-kit+
cell population is enriched with putative rat EPCs [23],
and the Sca-1+CD31+ phenotype can be taken to
represent the rat homologue of the humanCD34+KDR+.
Statistical analysis
Values are expressed as means+− S.E.M., unless where
specified. Progenitor cell count is expressed as cell
number/106 cytometric events. Comparison between
two or more groups was assessed using a Student’s t test
and ANOVA respectively. The LSD (least significance
difference) test was used for multiple testing. The χ2
test was used for frequencies and categorical variables.
A multiple regression analysis was built with the
EPC level as the dependent variable and sex hormone
concentrations as explanatory variables to determine any
independent associations. SPSS version 13.0 was used,
and statistical significance was set at P= 0.05.
RESULTS
EPCs and sex hormones in humans
The 62 men enrolled in the present study were repres-
entative of a middle-aged (mean+− S.D., 46.8+− 7.4 years)
population with a low prevalence of cardiovascular risk
factors. In the whole group, there was a non-significant
correlation between CD34+KDR+ EPC levels and E2
(r= 0.20; P= 0.10) or testosterone (r=−0.19; P= 0.12)
concentrations. A significant correlation was found
between EPC levels and the testosterone/E2 ratio
(r=−0.33; P = 0.006). Men were then divided into
four groups according to their median levels of E2 and
testosterone concentrations: group 1, high testosterone
with high E2 (n= 20); group 2, high testosterone with
low E2 (n= 14); group 3, low testosterone with high
E2 (n= 14); group 4, low testosterone with low E2
(n= 14). Clinical characteristics of these four groups
are shown in Table 1. Among the groups, there were
minimal differences in BMI and lipid profile, whereas the
other cardiovascular risk parameters were comparable.
In terms of EPC levels, the only significant difference
was between groups 2 and 3 (48.5+− 13.2 compared with
82.0+− 29.7; P= 0.035; Figure 1). A multiple regression
analysis, including all of the variables listed in Table 1
as determinants of EPC levels, showed that E2 was
positively associated with EPC levels, independently of
testosterone (standardized β = 0.28; P = 0.05). Taken
together, these results suggest that E2 is a stronger
determinant of EPCs than testosterone.
Phenotype of late EPCs
To isolate late EPCs, we employed a culture method
without pre-plating. This assay leads to purification of a
population of blood-derived cells with a true endothelial
phenotype and proliferative potential. During the first
few days of culture, the cell population is heterogeneous.
Subsequently, a change of medium and removal of
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Table 1 Characteristics of the healthy middle-aged men divided into the four groups according to their median E2 and
testosterone concentrations
Values are means+− S.D. Comparisons were performed with post-ANOVA LSD. *Significantly different compared with group 4 (Low E2/Low T); **significantly different
compared with group 1 (High E2/High T); ***significantly different compared with group 2 (Low E2/High T). T, testosterone.
Characteristic High E2/High T (n = 20) Low E2/High T (n = 14) High E2/Low T (n = 14) Low E2/Low T (n = 14)
Age (years) 47.7+− 6.8 45.9+− 7.1 45.4+− 7.0 48.0+− 9.1
Smoking habit (%) 15 21 0 7
Family history (%) 55 43 36 57
BMI (kg/m2) 26.4+− 4.0 26.4+− 3.6 28.8+− 3.8* 25.9+− 4.0
Waist circumference (cm) 97.0+− 8.0 96.8+− 10.4 100.6+− 11.1 94.5+− 11.0
Systolic BP (mmHg) 131.0+− 10.3 129.3+− 10.1 130.9+− 16.6 127.1+− 7.3
Diastolic BP (mmHg) 90.4+− 9.3 86.9+− 7.4 88.9+− 10.4 85.7+− 7.6
Plasma glucose (mg/dl) 94.3+− 10.4 93.9+− 10.4 98.2+− 17.9 91.0+− 15.0
Total cholesterol (mg/dl) 197.7+− 28.4 201.3+− 30.4 210.8+− 23.7 214.5+− 18.4
HDL-cholesterol (mg/dl) 49.4+− 11.7 42.3+− 6.8** 44.0+− 6.5 43.9+− 11.1
LDL-cholesterol (mg/dl) 128.1+− 22.4 138.5+− 28.5 143.7+− 25.9 147.6+− 22.3**
Triacylglycerols (mg/dl) 101.0+− 48.3 102.5+− 41.6 115.6+− 50.5 114.8+− 55.3
E2 (pg/ml) 19.2+− 2.4 13.9+− 2.4 18.6+− 2.1 13.6+− 2.3
Total testosterone (pg/ml) 20.7+− 4.7 16.8+− 3.3 11.5+− 1.5 11.0+− 2.8
CD34+KDR+ EPCs (per 106 events) 61.6+− 22.1 48.5+− 13.2 82.0+− 29.7*** 61.2+− 22.8
non-adherent cells allows a progressive selection of
cells with an endothelial-like morphology organizing in
clusters and colonies (Figures 2A and 2B). After 15 days
of culture, virtually all cells on the plate display an
endothelial behaviour, as demonstrated by the uptake
of AcLDL, binding of Ulex lectin and expression of
typical endothelial markers, such as KDR [VEGFR-2
(vascular endothelial growth factor receptor-2)], CD31
and vWf (Figures 2C–2J). We confirmed the expression
of CD31 and KDR using both IF and flow cytometry
(Figures 2N–2R). These cells in vitro were also positive
for CD34, revealing a very similar EPC phenotype
to the one determined ex vivo with flow cytometry
(CD34+KDR+). To have a final functional demonstration
that isolated cells behave like EPCs in vivo, we injected
them into rat muscles subjected to ischaemia/reperfusion
injury. At 2 weeks after the ischaemic damage, injected
cells were clearly incorporated into the endothelial layer
of the host vasculature, suggesting that they take part in
angiogenetic processes (Figure 2M).
Androgens have no effects on late EPC
expansion in vitro
In a separate set of experiments (n= 3 each), the medium
used to culture late EPCs was supplemented with 1, 10
or 100 nmol/l testosterone, DHT or E2. Cell clusters
were counted every 3 days after plating as a measure of
cell proliferation. Although the AUC of the number of
clusters over time reflects the proliferative kinetics, cell
clusters at day 15 is taken to represent the EPC yield and
the end of the culture protocol. Both of these parameters
were not significantly influenced by testosterone and
DHT supplementation at any concentration (Figures 3A
and 3B). Conversely, 10 nmol/l E2 was sufficient to
increase the cluster numbers andAUCof EPC expansion
at day 15 (Figures 3A and 3B).
Androgens have no effects on late EPC
adhesion in vitro
As a functional assay, we studied the ability of EPCs
to adhere to a mature endothelial layer. This is a critical
property of EPCs in exerting their vasculoprotective
action by means of both re-endothelialization and
neoangiogenesis. Culture supplementation with
testosterone or DHT had no effect on EPC adhesion at
any concentration (Figure 3C). Conversely, 10 nmol/l
E2 was sufficient to increase the adhesive property of
EPCs to a mature layer of HUVECs (Figure 3C).
Androgens increase early EPCs
As a control experiment, we isolated early EPCs, which
were defined as DiI–AcLDL- and lectin-double-positive
cells 4 days after plating. Supplementation with 1 nmol/l
testosterone, 1 and 10 nmol/l DHT, and 10 and 100
nmol/l E2 during the 4-day culture protocol significantly
increased the generation of early EPCs from PBMCs,
as compared with the unsupplemented experiments
(Figure 3D).
AR and aromatase activity in late EPCs
Using IF, we have shown that cultured EPCs express
the AR (Figure 2K), but WB analysis indicated that this
expression was low compared with a prostate extract
(Figure 4A). Aromatase activity was very low as well:
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Figure 2 Characterization of EPCs cultured from healthy men
(A) Clusters/small colonies of EPCs at day 12. (B) Cobblestone monolayer of EPCs at day 15. (C–J) EPCs isolated from healthy male blood donors with a prolonged
standardized protocol take up AcLDL, bind Ulex lectin, and stain positive for CD31, KDR and vWf. (K) Cultured EPCs at 15 days also stain positive for the AR.
(L) A representative microphotograph of red (CMTMR)-labelled EPCs adhering on to the top of a HUVEC monolayer (nuclei are counterstained in blue). (M) A red
(CMTMR)-labelled EPC incorporated into the host capillary network (FITC–CD31) after transplantation into an ischaemic rat muscle (nuclei are counterstained in blue).
(N–R) The antigenic phenotype of EPCs was confirmed by flow cytometry as CD45−CD14−CD31+KDR+CD34+ . (A–L) Original magnification, × 20; (K) original
magnification, × 40; (M) original magnification, × 40 (zoom, × 2.5).
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Figure 3 Effects of androgens on EPC expansion and adhesion
(A) Testosterone and DHT supplementation had no effects on the number of EPC colonies in culture. (B) A similar trend was evident for the AUC of EPC colonies over
the 15 days of culture. (C) Testosterone and DHT had no effect on adhesion of EPCs to a HUVEC monolayer. E2 served as a positive control. (D) E2, testosterone and
DHT increased the generation of early AcLDL- and lectin-double-positive EPCs. *P  0.05 compared with basal. T, testosterone.
incubation of EPCs with 10 nmol/l testosterone for 24 h
induced approx. 0.03 nmol/l E2 in the culture medium
(Figure 4B). However, it should be noted that, in the
absence of a significant effect of androgens on cultured
EPCs, the issue of aromatase activity is of limited value.
Effect of castration on circulating rat
EPCs in vivo
It has been suggested that androgen deprivation in
hypogonadal men is associated with EPC depletion [17].
To verify this observation, we have used an animal
model of primary hypogonadism to simulate androgen
deprivation. At 4 weeks after castration, circulating
levels of Sca-1+c-kit+ cells and Sca-1+CD31+ cells
fell markedly compared with baseline (Figure 5). As
expected, there was also a decline in testosterone and
E2 concentrations. Testosterone supplementation for
2 weeks was able to restore testosterone concentrations
towards physiological levels, although it had modest and
non-significant effects on E2 levels. Supplementation
with either testosterone or DHT was unable to restore
progenitor cell levels toward the baseline values (Fig-
ure 5).No differences were seen in EPC levels after sham-
operation compared with baseline (results not shown).
DISCUSSION
The roles of androgens in the cardiovascular system are
not clearly defined. In clinical studies, both androgen
excess and deficiency have been reported to exert negative
effects on cardiovascular parameters and endothelial
function [24,25]. However, these studies may be con-
founded by the association between androgen deficiency,
oestrogen deficiency and classic cardiovascular risk
factors. EPCs represent an integrated part of the
cardiovascular system, as they are involved in endothelial
homoeostasis and angiogenesis [5]. Alterations in
EPC biology are recognized as modifiable pathogenic
biomarkers of cardiovascular risk and, at the same time,
therapeutic targets of drugs with vascular effects. Ways
to increase EPC levels are actively pursued through
different strategies ranging from available medication
to the frontiers of cell therapy. EPC assays have been
used to test the ‘endotheliotropic’ activity of many
drugs, including statins, ACEIs (angiotensin-converting
enzyme inhibitors), glitazones and oestrogens [16,26–28].
In the present study, we have shown that androgens
(testosterone and its active metabolite DHT) exert no di-
rect effect on late EPCs in vitro and in vivo, as shown
using standardized assays, including colony formation,
adhesion and response to androgen replacement in vivo.
These findings apparently contradict a previous report
showing modest but significant increases in EPC
proliferation, migration and colony formation after
treatment with a synthetic androgenic agonist [18].
There may be several reasons for this discrepancy,
including the use of a different AR agonist, but the most
important issue appears to be the cell culture method.
Foresta et al. [18] isolated putative EPCs according to
the colony forming unit assay first described by Hill
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Figure 4 Expression of the AR and aromatase activity in
EPCs
(A) WB analysis of the AR in cultured human EPCs (prostate extract was
used as a positive control). EPCs express the AR (see Figure 2K), but protein
quantification via WB analysis demonstrates a very low expression compared with
the positive control. (B) Non-significant and non-linear conversion of testosterone
into E2 by human EPCs in culture, suggesting low or absent aromatase activity.
T, testosterone.
et al. [29], which correspond to the so-called early
‘monocytic’ EPCs. Early EPCs are believed to reflect
a population of immune cells mimicking endothelial
cells [19,30,31]. These endothelial-like cells express
CD45 and CD14, and have a limited proliferation
capacity in culture, thus representing bloodmonocytes or
macrophages. In the present study, we isolated late EPCs
according to a highly standardized culture protocol and
extensively characterized these cells in vitro and in vivo.
These lateEPCs areCD45−CD14−CD34+KDR+CD31+
and AcLDL- and lectin-double-positive and, therefore,
phenotypically different frommonocytic cells. They also
behave like EPCs in vivo, being able to incorporate
in the host microvasculature after transplantation into
ischaemic limbs. Although late EPCs isolated in the
present study fulfil most criteria required to define
true EPCs, including in vivo activity, the most recent
methodological reviews suggest early EPCs have little
in common with endothelial cells and should not be
considered true EPCs [19,20,32]. Indeed, we confirm
that androgens stimulate early EPCs, but show that
androgens have no effects on late EPCs. Interestingly,
as observed previously [21], different methods to study
Figure 5 Effects of rat castration on sex hormones and EPCs
Upper panels, at 4 weeks after castration, testosterone concentrations were
significantly reduced and were partly restored by testosterone replacement.
Castration also lowered E2 levels, but testosterone and DHT replacement were
unable to restore E2 levels. Castration was followed by a profound reduction
of Sca-1+c-kit+ and Sca-1+CD31+ rat EPCs, whereas testosterone and DHT
supplementation were unable to restore their circulating levels. *P  0.05
compared with basal; †P  0.05 compared with castration. T, testosterone.
Lower panels, the gating strategy used to enumerate rat EPCs according to the
fluorescence intensity of PE–Sca-1, FITC–CD31 and FITC–c-kit antibodies. x- and
y-axis of the flow cytometry plots show arbitrary fluorescence units.
EPCs can yield different or even opposite results. On
the contrary, E2 appears to stimulate the function of
both early and late EPCs in vitro from male and
female donors [14,15,33], and its effects on EPCs have
also been substantiated in vivo [16,34]. Moreover, E2
regulates the EPC cycle for endometrial regeneration,
providing fertile women with a larger EPC pool for
cardiovascular homoeostasis [16]. These findings collect-
ively suggest that oestrogens are more important than an-
drogens in the regulationof endogenousEPCs in humans.
One point in favour of the effect of androgens
on human EPCs in vivo is the observation that
C© The Authors Journal compilation C© 2009 Biochemical Society
Androgens and endothelial progenitor cells 363
hypogonadal men have low levels of circulating EPCs
[17]. However, those hypogonadal men had low plasma
concentrations of both E2 and testosterone. Therefore
a reduction in EPC number could not be definitely
attributed to testosterone deficiency. The observation
that testosterone replacement in hypogonadal men
was followed by restoration of a normal EPC pool is
insufficient to support a direct effect of testosterone on
EPCs, because testosterone treatment also increased E2
concentrations, probably through aromatase activity.
In the present study, we have developed an experi-
mental model of primary hypogonadism by performing
castration in adult male rats. As observed in humans,
rat hypogonadism was associated with low testosterone
and E2 levels, and a profound reduction in circulating
Sca-1+c-kit+ and Sca-1+CD31+ progenitor cells, which
represent rat EPCs. However, replacement therapy with
an infusion of testosterone or DHTwas unable to restore
EPC levels. The most reasonable explanation for this
negative result is that testosterone replacementwas able to
partially restore testosterone but not E2 concentrations,
whereas DHT replacement could not generate E2, as
DHT is not substrate of aromatase. The incomplete
restoration of testosterone concentrations by exogenous
testosterone would be unlikely to explain the sustained
profound reduction in EPC levels, even if testosterone
had a direct effect on EPCs because a partial effect on
EPCs would be expected. The different gonadotropin
levels in the experimental model as compared with the
human condition are not likely to influence the effects of
androgen deficiency on EPCs, as long as a direct effect
of gonadotropins on EPCs is not assumed.
Taken together, the present experimental findings sug-
gest that androgens have no direct effects on true human
EPCs, and that E2 is likely to be the hormonal drive of
EPC regulation in men as well as in women. To support
this notion further in humans,we selected a sample ofmen
from the general population. Although we found no sig-
nificant correlationbetweenEPCs and either testosterone
orE2, therewas a significant negative correlation between
EPCs and the testosterone/E2 ratio, revealing a possible
complex interplay between oestrogens and androgens
in males, possibly influenced by aromatase activity.
This negative correlation might actually reveal an even
detrimental effect of testosterone on circulating EPCs.
Moreover, when subjects were divided into four groups
according to high or low levels of E2 and testosterone,
it appeared that high E2 with low testosterone was
associated with higher EPC levels than high testosterone
with low E2. Finally, a multivariable analyses identified
E2 as a determinant of EPC levels independently of
testosterone. These results in healthy men support our
experimental results indicating that androgens do not
stimulate EPCs. It remains to be determined whether
androgens eventually exert negative effects onEPCs. This
is clearly not an argument against the desirable effects of
androgen replacement in hypogonadal men, but does not
support the use of androgens to stimulate EPCs.
In conclusion, in the present study, we found no
evidence in support of a direct effect of androgens on
EPC biology. As observed in other settings, the methods
used to study EPCs are critically important and may
largely affect study results [20,21]. Importantly, as
already demonstrated in women, our results indicate
that E2 rather than testosterone is likely to be the major
hormonal drive of EPC kinetics in men.
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